Meta-analysis shows dual ICI therapy improves survival in advanced metastatic non-small cell lung cancer
New analysis shows dual immune therapy helps patients with advanced lung cancer live longer and delays disease growth
This meta-analysis evaluates dual immune checkpoint inhibitor therapy versus control treatments in patients with advanced or metastatic non-…
A large review of 6,369 patients found that using two immune checkpoint drugs together improved survival time compared to standard treatment…
